Tag:
China
Latest Headlines
Latest Headlines
Chinese drugmaker fights counterfeiting in Africa with SMS technology
China has often been maligned in Africa as the source of counterfeit drugs, a reputation that the government is not at all happy about. Chinese authorities this year even took the unusual step of defending their country against a report in a U.K. newspaper that it was a primary source of fake antimalarial drugs in Uganda and Tanzania.
JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets
Joint ventures with Chinese companies have been seen as a way for Big Pharma to get better traction in the exploding China market. But it is not a one-way street. Chinese companies see the tie-ups as a way to build their own capabilities and begin to tap lucrative Western markets.
GSK tries novel approach in emerging markets: price cuts
GlaxoSmithKline CFO Simon Dingemans has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale.
PPD's BioDuro opens Shanghai discovery lab
BioDuro, PPD's China-based drug discovery business, has opened a state-of-the-art facility in Shanghai, a lab the company says will help it cozy up to clients in the growing Asian biopharmaceutical world.
China arrests dozens, seizes tens of millions of counterfeit drugs
Counterfeit drugs manufactured in China and sold in the U.S. have become a plague on the industry, but China also suffers from counterfeits being sold to its own citizens.
Amgen forges Chinese JV for Vectibix
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.
Teva CEO plans to court Chinese market with generics, respiratory meds
Teva CEO Jeremy Levin thinks his company and China are a match made in heaven. The Israeli generics giant is, after all, adept at making and selling cheap drugs, which the fast-growing Chinese market needs. And Teva has a strong portfolio of respiratory treatments--perfect for a country beset by air pollution.
China backs its booming biopharma industry with big subsidies
China is in the middle of one of its 5-year economic plans, and it's got big plans for biopharma. China Daily reports that the sales revenue for the industry came close to $29 billion last year, up a whopping 18%. And the government is feeding about a half billion dollars in annual government support to keep the growth going at the same torrid pace.
Mindray soars in Q1 with 21% Dx growth
Mindray Medical, China's largest devicemaker, has been working to differentiate its business, and the effort paid off in the first quarter as the company's swelling diagnostics segment led the way to 10.5% revenue growth.
Sagent buys full control of China plant
The foundation of Sagent's model is in partnerships, but drug shortages and industry consolidation are changing the nature of the business and the U.S. company decided it wanted complete control of the $50 million plant, its first foray into owning a facility.
